XOMA Completes Acquisition of Entire Share Capital of Mural Oncology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy XOMA?
XOMA Royalty (XOMA) completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology (MURA) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland. Mural shareholders received $2.035 in cash per share. The Acquisition was approved by Mural shareholders at a special meeting of shareholders convened pursuant to section 450(1) of the Irish Companies Act 2014 and an extraordinary general meeting of shareholders held on October 24, 2025. The Irish High Court sanctioned the Scheme on December 3, 2025. On December 5, 2025, the Scheme and the Acquisition became effective upon delivery of the court order to the Irish Companies Registration Office. Prior to the opening of trading on December 5, 2025, all of Mural's shares will cease trading on Nasdaq, and Mural intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XOMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 71.00 USD with a low forecast of 50.00 USD and a high forecast of 97.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.860
Low
50.00
Averages
71.00
High
97.00
Current: 24.860
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XOMA Royalty Completes Acquisition of Generation Bio
- Acquisition Completion: XOMA Royalty has successfully completed its acquisition of Generation Bio, offering a cash price of $4.2913 per share along with a non-tradeable contingent value right, demonstrating the company's commitment to expanding in the biotechnology sector.
- Share Acceptance Rate: As of February 6, 2026, XOMA accepted 4,722,533 shares of Generation Bio, representing approximately 70% of its outstanding shares, satisfying the minimum tender condition and indicating market approval of the transaction.
- Post-Merger Outcome: Following the acquisition, Generation Bio has become a wholly owned subsidiary of XOMA, with all shares not validly tendered converting into cash rights, further solidifying XOMA's market position in biotechnology.
- Market Impact: This acquisition is expected to enhance XOMA's asset portfolio, creating new revenue opportunities for the future, while potentially boosting investor confidence in XOMA and driving its stock price upward.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock declines.
- Poor Clinical Trial Results: The Phase 3 sunRIZE study results released by Rezolute, Inc. indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, raising concerns about XOMA's future prospects in the market.
- Significant Stock Drop: Following the unfavorable news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 per share on December 19, 2025, reflecting investor disappointment in the company's outlook.
- Increased Legal Risks: As the investigation progresses, XOMA may face heightened legal liabilities and potential compensation claims, which could have long-term negative impacts on the company's financial health and market reputation.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- Disappointing Clinical Trial Results: Rezolute, Inc.'s Phase 3 sunRIZE study results indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, potentially impacting XOMA's market outlook.
- Significant Stock Drop: Following the adverse news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, reflecting market pessimism regarding the company's future.
- Increased Legal Risks: As the investigation unfolds, XOMA faces potential legal liabilities and compensation risks, which could adversely affect its financial condition and investor trust in the long term.
See More
XOMA Royalty CFO Thomas Burns Resigns, Jeffrey Trigilio Appointed
- Executive Change: XOMA Royalty's CFO Thomas Burns has resigned to pursue other professional opportunities, indicating a dynamic adjustment within the company's leadership team.
- New CFO Appointment: Jeffrey Trigilio has been appointed as the new CFO, bringing extensive industry experience from his previous role as Chief Financial and Operating Officer at Obsidian Therapeutics.
- Strategic Commitment: Trigilio emphasized the continuation of disciplined capital deployment and innovative deal structuring strategies to enhance the company's royalty portfolio and generate value for shareholders.
- Market Performance: In pre-market trading, XOMA's stock is priced at $29.97, reflecting a 0.40% increase, indicating a positive market reaction to the leadership change.
See More
XOMA Royalty CFO Thomas Burns Steps Down, Jeffrey Trigilio Appointed
- Executive Transition: XOMA Royalty's CFO Thomas Burns has stepped down after nearly 20 years, during which he established a strong financial foundation to support future growth, reflecting the company's stability amid leadership changes.
- New CFO Background: Jeffrey Trigilio has been appointed as the new CFO, bringing extensive experience from various biotech companies and investment banks, which is expected to drive the company's development forward.
- Strategic Direction: Trigilio emphasized the continuation of disciplined capital deployment and innovative deal structuring strategies aimed at enhancing the royalty portfolio and generating shareholder value, indicating the company's confidence in future growth.
- Market Positioning: As a biotechnology royalty aggregator, XOMA Royalty focuses on acquiring potential future economic benefits, assisting biotech firms in achieving their goals of improving human health, showcasing its unique role within the healthcare ecosystem.
See More
XOMA Shares Plunge 22.76% Following Phase 3 Study Failure
- Stock Price Plunge: Following the failure of Rezolute, Inc.'s Phase 3 sunRIZE study to meet its primary endpoint, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, indicating strong market concerns about its future prospects.
- Poor Study Results: The study only showed an approximate 45% reduction in hypoglycemia events at the highest dose of 10 mg/kg, which was not statistically significant compared to the placebo group's 40% improvement, reflecting limited drug efficacy that may impact future R&D investments.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether XOMA and its executives engaged in securities fraud or other unlawful business practices, signaling a severe blow to investor confidence in corporate governance and transparency, which could lead to further legal risks.
- Market Reaction Strong: This significant stock price drop not only undermines investor confidence but may also negatively affect XOMA's ability to secure financing and future partnerships, exacerbating market skepticism about its business model.
See More
XOMA Royalty Completes Acquisition of Generation Bio
- Acquisition Completion: XOMA Royalty has successfully completed its acquisition of Generation Bio, offering a cash price of $4.2913 per share along with a non-tradeable contingent value right, demonstrating the company's commitment to expanding in the biotechnology sector.
- Share Acceptance Rate: As of February 6, 2026, XOMA accepted 4,722,533 shares of Generation Bio, representing approximately 70% of its outstanding shares, satisfying the minimum tender condition and indicating market approval of the transaction.
- Post-Merger Outcome: Following the acquisition, Generation Bio has become a wholly owned subsidiary of XOMA, with all shares not validly tendered converting into cash rights, further solidifying XOMA's market position in biotechnology.
- Market Impact: This acquisition is expected to enhance XOMA's asset portfolio, creating new revenue opportunities for the future, while potentially boosting investor confidence in XOMA and driving its stock price upward.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock declines.
- Poor Clinical Trial Results: The Phase 3 sunRIZE study results released by Rezolute, Inc. indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, raising concerns about XOMA's future prospects in the market.
- Significant Stock Drop: Following the unfavorable news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 per share on December 19, 2025, reflecting investor disappointment in the company's outlook.
- Increased Legal Risks: As the investigation progresses, XOMA may face heightened legal liabilities and potential compensation claims, which could have long-term negative impacts on the company's financial health and market reputation.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- Disappointing Clinical Trial Results: Rezolute, Inc.'s Phase 3 sunRIZE study results indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, potentially impacting XOMA's market outlook.
- Significant Stock Drop: Following the adverse news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, reflecting market pessimism regarding the company's future.
- Increased Legal Risks: As the investigation unfolds, XOMA faces potential legal liabilities and compensation risks, which could adversely affect its financial condition and investor trust in the long term.
See More
XOMA Royalty CFO Thomas Burns Resigns, Jeffrey Trigilio Appointed
- Executive Change: XOMA Royalty's CFO Thomas Burns has resigned to pursue other professional opportunities, indicating a dynamic adjustment within the company's leadership team.
- New CFO Appointment: Jeffrey Trigilio has been appointed as the new CFO, bringing extensive industry experience from his previous role as Chief Financial and Operating Officer at Obsidian Therapeutics.
- Strategic Commitment: Trigilio emphasized the continuation of disciplined capital deployment and innovative deal structuring strategies to enhance the company's royalty portfolio and generate value for shareholders.
- Market Performance: In pre-market trading, XOMA's stock is priced at $29.97, reflecting a 0.40% increase, indicating a positive market reaction to the leadership change.
See More
XOMA Royalty CFO Thomas Burns Steps Down, Jeffrey Trigilio Appointed
- Executive Transition: XOMA Royalty's CFO Thomas Burns has stepped down after nearly 20 years, during which he established a strong financial foundation to support future growth, reflecting the company's stability amid leadership changes.
- New CFO Background: Jeffrey Trigilio has been appointed as the new CFO, bringing extensive experience from various biotech companies and investment banks, which is expected to drive the company's development forward.
- Strategic Direction: Trigilio emphasized the continuation of disciplined capital deployment and innovative deal structuring strategies aimed at enhancing the royalty portfolio and generating shareholder value, indicating the company's confidence in future growth.
- Market Positioning: As a biotechnology royalty aggregator, XOMA Royalty focuses on acquiring potential future economic benefits, assisting biotech firms in achieving their goals of improving human health, showcasing its unique role within the healthcare ecosystem.
See More
XOMA Shares Plunge 22.76% Following Phase 3 Study Failure
- Stock Price Plunge: Following the failure of Rezolute, Inc.'s Phase 3 sunRIZE study to meet its primary endpoint, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, indicating strong market concerns about its future prospects.
- Poor Study Results: The study only showed an approximate 45% reduction in hypoglycemia events at the highest dose of 10 mg/kg, which was not statistically significant compared to the placebo group's 40% improvement, reflecting limited drug efficacy that may impact future R&D investments.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether XOMA and its executives engaged in securities fraud or other unlawful business practices, signaling a severe blow to investor confidence in corporate governance and transparency, which could lead to further legal risks.
- Market Reaction Strong: This significant stock price drop not only undermines investor confidence but may also negatively affect XOMA's ability to secure financing and future partnerships, exacerbating market skepticism about its business model.
See More
